Feb. 2 at 2:46 PM
$VKTX
I recall holding
$AXSM for a few years during its P3 clinical stage of what is now its blockbuster MDD drug, Auvelity. Shorts decimated its SP from
$110 to
$20. Whether the ST posters were the same or not, the messaging was *identical* to what we're seeing today. And, yes, it took a couple of years for the SP to recover.
Its story to commercialization is fascinating and worth your investigating. People complained they didn't have a marketing team and lacked the funds to build one. And yet, in a couple of brilliant moves, not only did they build one - inherited it, actually - they *made* money doing it while acquiring another blockbuster drug, Sanofi, from Jazz.
Viking's TAM absolutely dwarfs Axsome's, and its ability to take share in the metabolic sector dramatically outstrips Axsome's in CNS.
Know what you own. I bought Axsome at
$40 and weathered the storm. Today, Axsome trades in the
$180 s. Viking will pass
$180 as a speed bump on its way to
$1000+.
Long hold. Very...
